Would you use taxanes in the treatment of patients with metastatic small bowel adenocarcinoma once the disease progressed on oxaliplatin/5FU/irinotecan based regimens ?

NCCN guidelines lists multiple taxanes and combination as potential treatment option based on very weak evidence (single institution retrospective review- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656507/)